New Delhi, May 24th 2026: Anupam Rasayan India Ltd. (BSE- 543275, NSE- ANURAS, ISIN: INE930P01018), one of India’s leading custom synthesis and specialty chemical player, has announced its financial results for the quarter and year endedMarch 31, 2026.
| Particulars (Rs. In Mn) | Q4FY26 | Q4FY25 | YoY (%) | FY26 | FY25 | YoY (%) |
| Total Revenue | 6,392 | 5,057 | 26% | 23,836 | 14,485 | 65% |
| EBITDA | 1,407 | 1,500 | -6% | 5,430 | 4,123 | 32% |
| EBITDA Margin | 22% | 30% | 23% | 28% | ||
| PAT | 560 | 629 | -11% | 2,222 | 1,600 | 39% |
Consolidated Financial Highlights for year ended March 31, 2026:
- Total Revenue for FY26 was Rs 23,836 Mn as compared to Rs 14,485 Mn in FY25; up 65% YoY
- EBITDA (incl. other income) came in at Rs 5,430 Mn in FY26 as against Rs 4,123 Mn in FY25; up 32% YoY, translating into EBITDA margin of 23% for the full year.
- Profit After Tax stood at Rs 2,222 Mn in FY26 as compared to Rs 1,600 crores in FY25
Consolidated Financial Highlights for Quarter ended March 31, 2026:
- Total Revenue for Q4FY26 was at Rs 6,392 Mn as compared to Rs 5,057 Mn in Q4FY25; up 26 % YoY
- EBITDA (incl. other income) came in at Rs 1,407 Mn in Q4FY26 as against Rs 1,500 Mn in Q4FY25; down 6% YoY, translating into EBITDA margin of 22% for Q4FY26.
- Profit After Tax stood at Rs 560 Mn in Q4FY26 as compared to Rs 629 Mn in Q4FY25
Commenting on the performance, Mr. Anand Desai, Managing Director, Anupam Rasayan India Ltd., said “We are pleased to share that FY26 has been a landmark year for Anupam Rasayan, marked by strong operational execution, strategic expansion, and continued progress toward building a globally integratedspecialty chemicals and CDMO platform. During the year, the Company achieved its highest-ever annual sales and operating cash flow performance, reflecting robust business momentum, operational efficiency, and strong cash generation. Growth was driven by commercializationof new products, addition of new multinational customers, and expanding engagements across key business verticals.
We continue to strengthen our presence in niche and complex chemistries where technical expertise and long qualification cycles create strong entry barriers and sustainable growth opportunities.
A key strategic milestone during the year was the successful acquisition of Jayhawk Fine Chemicals in the United States. Jayhawk delivered strong proforma revenue of US$ 95Mn, reinforcing the strategicvalue of the acquisition and strengthening our global manufacturing footprint, advanced chemistry capabilities, and integrated CDMO platform. The acquisition also enhances our access to regulated markets and innovator customers across North America.
Additionally, we have signed a definitive agreement to acquire Bliss GVS Pharma which will further strengthen
our pharmaceutical value chain capabilities and is expected to create meaningful synergies across CDMO capabilities, product portfolio, and customer relationships.
Looking ahead, we remain well-positioned for the next phase of growth, supported by increasing contribution from Performance Materials and Pharma segment, a strong product pipeline, and expanding globalcustomer engagements.”
